Inhibition of Super-Enhancer Activity in Autoinflammatory Site-Derived T Cells Reduces Disease-Associated Gene Expression

Cell Reports

Volumn 12, Issue 12, 2015, Pages 1986-1996

  Peeters, Janneke G C ^a   Vervoort, Stephin J ^a   Tan, Sander C ^a   Mijnheer, Gerdien ^a,b   de Roock, Sytze ^a,b   Vastert, Sebastiaan J ^a,b   Nieuwenhuis, Edward E S ^b   van Wijk, Femke ^a,b   Prakken, Berent J ^a,b   Creyghton, Menno P ^a   Coffer, Paul J ^a,b   Mokry, Michal ^b   Van Loosdregt, Jorg ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; BROMODOMAIN INHIBITOR; CHEMOKINE RECEPTOR CXCR4; CYTOKINE; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR RUNX1; (+)-JQ1 COMPOUND; AZEPINE DERIVATIVE; CXCL12 PROTEIN, HUMAN; CYTOKINE RECEPTOR; ETS1 PROTEIN, HUMAN; NONSTEROID ANTIINFLAMMATORY AGENT; ONCOPROTEIN; RUNX1 PROTEIN, HUMAN; STROMAL CELL DERIVED FACTOR 1; TRIAZOLE DERIVATIVE;

ARTICLE; CD4+ T LYMPHOCYTE; CHILD; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CONTROLLED STUDY; EFFECTOR CELL; ENHANCER REGION; GENE EXPRESSION; HUMAN; HUMAN CELL; JUVENILE RHEUMATOID ARTHRITIS; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; RNA SEQUENCE; SYNOVIAL FLUID; T LYMPHOCYTE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, JUVENILE; AUTOIMMUNITY; CYTOLOGY; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; HIGH THROUGHPUT SEQUENCING; IMMUNOLOGICAL MEMORY; METABOLISM; MOLECULAR GENETICS; MONONUCLEAR CELL; NUCLEOTIDE SEQUENCE; PATHOLOGY; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, JUVENILE; AUTOIMMUNITY; AZEPINES; BASE SEQUENCE; CHEMOKINE CXCL12; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CYTOKINES; ENHANCER ELEMENTS, GENETIC; EPIGENESIS, GENETIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOLOGIC MEMORY; LEUKOCYTES, MONONUCLEAR; MOLECULAR SEQUENCE DATA; PRIMARY CELL CULTURE; PROTO-ONCOGENE PROTEIN C-ETS-1; PROTO-ONCOGENE PROTEINS; RECEPTORS, CYTOKINE; SIGNAL TRANSDUCTION; SYNOVIAL FLUID; T-LYMPHOCYTES; TRIAZOLES;

EID: 84942819233     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.08.046     Document Type: Article

References (26)

1. Bandukwala H.S., Gagnon J., Togher S., Greenbaum J.A., Lamperti E.D., Parr N.J., Molesworth A.M.H., Smithers N., Lee K., Witherington J., et al. Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors. Proc. Natl. Acad. Sci. USA 2012, 109:14532-14537.
2. Bernstein B.E., Stamatoyannopoulos J.A., Costello J.F., Ren B., Milosavljevic A., Meissner A., Kellis M., Marra M.A., Beaudet A.L., Ecker J.R., et al. The NIH Roadmap Epigenomics Mapping Consortium. Nat. Biotechnol. 2010, 28:1045-1048.
3. Brown J.D., Lin C.Y., Duan Q., Griffin G., Federation A.J., Paranal R.M., Bair S., Newton G., Lichtman A.H., Kung A.L., et al. NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis. Mol. Cell 2014, 56:219-231.
4. Chipumuro E., Marco E., Christensen C.L., Kwiatkowski N., Zhang T., Hatheway C.M., Abraham B.J., Sharma B., Yeung C., Altabef A., et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell 2014, 159:1126-1139.
5. Creyghton M.P., Cheng A.W., Welstead G.G., Kooistra T., Carey B.W., Steine E.J., Hanna J., Lodato M.A., Frampton G.M., Sharp P.A., et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl. Acad. Sci. USA 2010, 107:21931-21936.
6. de Jager W., Prakken B.J., Bijlsma J.W.J., Kuis W., Rijkers G.T. Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. J. Immunol. Methods 2005, 300:124-135.
7. Delmore J.E., Issa G.C., Lemieux M.E., Rahl P.B., Shi J., Jacobs H.M., Kastritis E., Gilpatrick T., Paranal R.M., Qi J., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
8. Farh K.K.-H., Marson A., Zhu J., Kleinewietfeld M., Housley W.J., Beik S., Shoresh N., Whitton H., Ryan R.J.H., Shishkin A.A., et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 2015, 518:337-343.
9. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., Morse E.M., Keates T., Hickman T.T., Felletar I., et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
10. Finkel, T.H., Zhang, H., and Hakonarson, H. May 2013. CXCR4 as a susceptibility locus in juvenile idiopathic arthritis (JIA) and methods of use thereof for the treatment and diagnosis of the same. Patent WO2012065100 A2.
11. Hnisz D., Abraham B.J., Lee T.I., Lau A., Saint-André V., Sigova A.A., Hoke H.A., Young R.A. Super-enhancers in the control of cell identity and disease. Cell 2013, 155:934-947.
12. Klein K., Kabala P.A., Grabiec A.M., Gay R.E., Kolling C., Lin L.-L., Gay S., Tak P.P., Prinjha R.K., Ospelt C., Reedquist K.A. The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts. Ann. Rheum. Dis. 2014, Published online December 2, 2014. 10.1136/annrheumdis-2014-205809.
13. Klunker S., Chong M.M.W., Mantel P.-Y., Palomares O., Bassin C., Ziegler M., Rückert B., Meiler F., Akdis M., Littman D.R., Akdis C.A. Transcription factors RUNX1 and RUNX3 in the induction and suppressive function of Foxp3+ inducible regulatory T cells. J. Exp. Med. 2009, 206:2701-2715.
14. Lovén J., Hoke H.A., Lin C.Y., Lau A., Orlando D.A., Vakoc C.R., Bradner J.E., Lee T.I., Young R.A. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013, 153:320-334.
15. Mansour M.R., Abraham B.J., Anders L., Berezovskaya A., Gutierrez A., Durbin A.D., Etchin J., Lawton L., Sallan S.E., Silverman L.B., et al. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 2014, 346:1373-1377.
16. Meda F., Folci M., Baccarelli A., Selmi C. The epigenetics of autoimmunity. Cell. Mol. Immunol. 2011, 8:226-236.
17. Mele D.A., Salmeron A., Ghosh S., Huang H.-R., Bryant B.M., Lora J.M. BET bromodomain inhibition suppresses TH17-mediated pathology. J. Exp. Med. 2013, 210:2181-2190.
18. Nicodeme E., Jeffrey K.L., Schaefer U., Beinke S., Dewell S., Chung C.-W., Chandwani R., Marazzi I., Wilson P., Coste H., et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010, 468:1119-1123.
19. Parker S.C.J., Stitzel M.L., Taylor D.L., Orozco J.M., Erdos M.R., Akiyama J.A., van Bueren K.L., Chines P.S., Narisu N., Black B.L., et al. Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants. Proc. Natl. Acad. Sci. USA 2013, 110:17921-17926. NISC Comparative Sequencing Program, National Institutes of Health Intramural Sequencing Center Comparative Sequencing Program AuthorsNational Institutes of Health Intramural Sequencing Center Comparative Sequencing Program Authors, NISC Comparative Sequencing Program AuthorsNISC Comparative Sequencing Program Authors.
20. Prakken B., Albani S., Martini A. Juvenile idiopathic arthritis. Lancet 2011, 377:2138-2149.
21. Redlich K., Kiener H.P., Schett G., Tohidast-Akrad M., Selzer E., Radda I., Stummvoll G.H., Steiner C.W., Gröger M., Bitzan P., et al. Overexpression of transcription factor Ets-1 in rheumatoid arthritis synovial membrane: regulation of expression and activation by interleukin-1 and tumor necrosis factor alpha. Arthritis Rheum. 2001, 44:266-274.
22. Schmidl C., Hansmann L., Lassmann T., Balwierz P.J., Kawaji H., Itoh M., Kawai J., Nagao-Sato S., Suzuki H., Andreesen R., et al. The enhancer and promoter landscape of human regulatory and conventional T-cell subpopulations. Blood 2014, 123:e68-e78. FANTOM consortium.
23. Seumois G., Chavez L., Gerasimova A., Lienhard M., Omran N., Kalinke L., Vedanayagam M., Ganesan A.P.V., Chawla A., Djukanović R., et al. Epigenomic analysis of primary human T cells reveals enhancers associated with TH2 memory cell differentiation and asthma susceptibility. Nat. Immunol. 2014, 15:777-788.
24. Vahedi G., Kanno Y., Furumoto Y., Jiang K., Parker S.C.J., Erdos M.R., Davis S.R., Roychoudhuri R., Restifo N.P., Gadina M., et al. Super-enhancers delineate disease-associated regulatory nodes in T cells. Nature 2015, 520:558-562.
25. Whyte W.A., Orlando D.A., Hnisz D., Abraham B.J., Lin C.Y., Kagey M.H., Rahl P.B., Lee T.I., Young R.A. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 2013, 153:307-319.
26. Zuber J., Shi J., Wang E., Rappaport A.R., Herrmann H., Sison E.A., Magoon D., Qi J., Blatt K., Wunderlich M., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478:524-528.